| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.09 | 0.04 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.076 | 0.04 |
| mRNA | NSC95397 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.04 |
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | 0.076 | 0.04 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.073 | 0.04 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | 0.071 | 0.05 |
| mRNA | JW-480 | CTRPv2 | pan-cancer | AAC | 0.075 | 0.05 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.072 | 0.05 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.05 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.05 |